Gray or Dark Spot in the Center of Your Vision

The macula is a small but critical zone at the center of the retina, the light-sensitive tissue that lines the back wall of the eye. It is densely packed with photoreceptor cells (the specialized cells that detect light and color) and is responsible for the sharp vision you use to read, recognize faces, drive, and see fine detail. When disease damages these cells or disturbs the macula's delicate layered structure, the brain stops receiving clear signals from the central visual field. The result is a dark, gray, or blurry patch in the center of your vision. Because the surrounding peripheral retina is typically spared, most people retain some side vision even when central vision is significantly reduced.

Wet AMD is one of the most common and urgent causes of a suddenly appearing central dark spot. In wet AMD, abnormal blood vessels grow beneath the retina and leak fluid or blood into the macula. This leakage rapidly disrupts the macular structure and can produce a noticeable dark or blurry area that develops over hours to days. Without treatment, these leaking vessels can cause scarring and permanent central vision loss. Anti-VEGF injections (medications that block the protein driving abnormal vessel growth) are the standard treatment and can stabilize or improve vision in many patients when started promptly. Age-related macular degeneration is the leading cause of central vision loss in adults over 50.

Dry AMD is the more common form of age-related macular degeneration. In its advanced stage, known as geographic atrophy, the retinal pigment epithelium (a supportive cell layer beneath the retina) and the photoreceptor cells it nourishes gradually deteriorate. This produces a slowly expanding dark or gray region in the central vision. Unlike wet AMD, which can develop within days, geographic atrophy progresses over months to years. The dark spot often begins at the edges of central vision before eventually involving the very center of fixation.

A macular hole is a small, full-thickness opening that forms in the central macular tissue. It typically develops when the vitreous (the clear, gel-like substance that fills the eye) pulls on the macula as it naturally separates from the retinal surface with age. This traction can tear a hole directly through the center of the macula. Along with a central dark or gray spot, patients often notice metamorphopsia, a type of visual distortion in which straight lines appear bent, wavy, or broken. Idiopathic macular holes, meaning those without a specific identifiable external cause, account for the large majority of cases and are more common in women and in people over 60. Most macular holes gradually enlarge if left untreated.

Macular edema is a buildup of fluid within the layers of the macular tissue that causes the retina to swell. This swelling distorts the macula's architecture and produces blurry or darkened central vision. Macular edema can result from diabetic retinopathy (retinal damage caused by diabetes), retinal vein occlusion (a blockage of a blood vessel draining the retina), uveitis (inflammation inside the eye), or as a complication following cataract surgery. Treating macular edema requires addressing both the fluid accumulation and the underlying condition causing it.

Central serous chorioretinopathy (CSC) occurs when fluid accumulates beneath the macula, most often in younger adults experiencing high levels of stress or using corticosteroid medications. It typically produces a blurry, dimmed, or slightly distorted central area that often resolves on its own but can recur or become chronic with time. Macular dystrophies such as Stargardt disease are inherited conditions that progressively damage the macula and can cause central scotomas in younger patients. Conditions affecting the optic nerve can also reduce central vision, though the pattern and characteristics often differ from macular disease. A thorough retinal evaluation is needed to identify the specific cause in any individual case.

In wet AMD, OCT imaging typically reveals fluid beneath or within the macula, and fluorescein angiography may show the leaking abnormal blood vessels responsible for the damage. Treatment with anti-VEGF injection therapy is the established standard of care, beginning with a series of injections and continuing on a schedule tailored to how your macula responds. Early treatment gives the best opportunity to stabilize vision, and some patients achieve meaningful improvement with consistent therapy. Our team monitors treatment response at every visit using repeat OCT imaging.

Geographic atrophy is identified by well-defined areas of retinal cell loss that are clearly visible on fundus autofluorescence imaging and confirmed with OCT showing thinning of the outer retinal layers. Complement inhibitor therapies, which target a part of the immune system involved in the progressive cell death of geographic atrophy, are now approved and have demonstrated the ability to slow the expansion of atrophic areas. While these treatments cannot restore cells that have already been lost, slowing progression helps preserve more functional vision over time. Your retina specialist will discuss whether these treatments are appropriate for your stage of disease and monitor your response with regular imaging.

OCT imaging precisely identifies a macular hole as a full-thickness gap in the central macular tissue. The size and stage of the hole are carefully assessed, as these factors influence the expected outcome of treatment. Vitrectomy surgery is the standard treatment, in which the vitreous gel is removed and a small gas bubble is placed inside the eye to press the edges of the hole together while healing takes place. The large majority of macular holes close successfully after vitrectomy, and many patients experience meaningful recovery of central vision. Smaller holes and those treated earlier tend to have better outcomes. Your surgeon will provide detailed instructions for the required head-positioning period following surgery.

Macular edema is confirmed with OCT imaging, which shows increased retinal thickness and fluid-filled spaces within the macular layers. Treatment depends on the underlying cause and typically includes anti-VEGF injections, intravitreal corticosteroid (steroid) injections, or sustained-release corticosteroid implants. For patients with diabetic macular edema, our team works in coordination with primary care physicians and endocrinologists to address the systemic factors, including blood sugar and blood pressure control, that directly influence macular health over the long term.